- Home
- GENI vs AGIO Comparison
GENI vs AGIO Comparison
Compare GENI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- AGIO
- Stock Information
- Founded
- GENI 2016
- AGIO 2007
- Country
- GENI United Kingdom
- AGIO United States
- Employees
- GENI N/A
- AGIO N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- AGIO Health Care
- Exchange
- GENI Nasdaq
- AGIO Nasdaq
- Market Cap
- GENI 2.5B
- AGIO 2.5B
- IPO Year
- GENI N/A
- AGIO 2013
- Fundamental
- Price
- GENI $9.92
- AGIO $29.09
- Analyst Decision
- GENI Strong Buy
- AGIO Buy
- Analyst Count
- GENI 17
- AGIO 9
- Target Price
- GENI $13.76
- AGIO $32.13
- AVG Volume (30 Days)
- GENI 6.8M
- AGIO 2.3M
- Earning Date
- GENI 11-04-2025
- AGIO 10-30-2025
- Dividend Yield
- GENI N/A
- AGIO N/A
- EPS Growth
- GENI N/A
- AGIO N/A
- EPS
- GENI N/A
- AGIO N/A
- Revenue
- GENI $604,524,000.00
- AGIO $44,791,000.00
- Revenue This Year
- GENI $28.54
- AGIO $25.57
- Revenue Next Year
- GENI $17.14
- AGIO $153.24
- P/E Ratio
- GENI N/A
- AGIO N/A
- Revenue Growth
- GENI 30.70
- AGIO 36.26
- 52 Week Low
- GENI $8.15
- AGIO $22.24
- 52 Week High
- GENI $13.73
- AGIO $62.45
- Technical
- Relative Strength Index (RSI)
- GENI 44.01
- AGIO 36.49
- Support Level
- GENI $8.59
- AGIO $23.00
- Resistance Level
- GENI $10.51
- AGIO $25.98
- Average True Range (ATR)
- GENI 0.43
- AGIO 2.23
- MACD
- GENI 0.05
- AGIO -1.57
- Stochastic Oscillator
- GENI 69.66
- AGIO 29.12
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.